falsefalse

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 7

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

,

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of HR+, HER2- Metastatic Breast Cancer
    EP. 2: Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
    EP. 3: The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
    EP. 4: Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
    EP. 5: CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
    EP. 6: The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
    Now Viewing
    EP. 7: The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
    EP. 8: Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
    EP. 9: Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

    Related Content:

    Emerging Therapies in the Management of HR+, HER2- Metastatic Breast CancerOncLive News Network®Breast Cancer
    Health Canada Approves Adjuvant Ribociclib for HR+/HER2– Early Breast Cancer
    Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management
    Recent Shifts in the Management of Lower-Risk MDS
    x